Researchers have developed a novel nanocomposite made of graphene oxide and the enzyme lactoperoxidase that shows promising anti-cancer properties against colon cancer cells. Graphene oxide, a highly versatile nanomaterial, is modified with the natural biopolymer alginate and then combined with the powerful enzyme lactoperoxidase to create a potent anti-cancer agent.
This innovative nanocomposite demonstrates superior selectivity in targeting colon cancer cells while leaving normal cells unharmed. The researchers found that the modified graphene oxide-lactoperoxidase nanocomposite was able to induce apoptosis, or programmed cell death, in colon cancer cells through the regulation of key genes involved in cancer progression. Additionally, the nanocomposite was able to suppress the expression of pro-inflammatory markers, which play a crucial role in tumor growth and metastasis.
The findings of this study suggest that this novel nanocomposite could offer a promising new approach for the treatment of colon cancer, a leading cause of cancer-related deaths worldwide. The ability to selectively target cancer cells while minimizing harm to healthy tissues is a crucial advantage in developing more effective and safer cancer therapies.
Graphene Oxide: A Versatile Nanomaterial for Cancer Therapy
Graphene oxide is a remarkable nanomaterial that has gained significant attention in the field of cancer research and therapy. This single-layer carbon material with various oxygen-containing functional groups, such as epoxide, hydroxyl, and carboxyl groups, has unique properties that make it an attractive candidate for cancer treatment. Graphene oxide can be used as a drug carrier, delivering anti-cancer agents directly to tumor cells, and it can also exert its own inhibitory effects on cancer cell growth and proliferation.
The researchers in this study leveraged the unique properties of graphene oxide to create a novel nanocomposite for targeting colon cancer. By modifying the graphene oxide with the natural biopolymer alginate, the researchers were able to improve the stability and biocompatibility of the nanocomposite, making it more suitable for biomedical applications.
Lactoperoxidase: A Powerful Enzyme with Anti-Cancer Potential
Lactoperoxidase is an enzyme found in various bodily secretions, such as milk, saliva, and tears. This enzyme plays a crucial role in the body’s innate immune system, exhibiting antimicrobial and antioxidant properties. Interestingly, recent studies have also suggested that lactoperoxidase may have potential anti-cancer effects, making it an attractive candidate for cancer therapy.
In this study, the researchers combined the modified graphene oxide with the purified lactoperoxidase enzyme to create a unique nanocomposite with enhanced anti-cancer properties. The researchers hypothesized that the combination of graphene oxide’s tumor-targeting abilities and lactoperoxidase’s anti-cancer effects would result in a potent and selective treatment for colon cancer.
Characterization and Evaluation of the Graphene Oxide-Lactoperoxidase Nanocomposite
The researchers used various analytical techniques to thoroughly characterize the graphene oxide-lactoperoxidase nanocomposite. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) revealed the successful adsorption of lactoperoxidase onto the surface of the modified graphene oxide. Fourier-transform infrared spectroscopy (FTIR) and Raman spectroscopy confirmed the presence of the enzyme and the interactions between the graphene oxide and lactoperoxidase.
Importantly, the researchers also evaluated the stability of the lactoperoxidase enzyme in its free form and when incorporated into the nanocomposite. They found that the nanoformulation significantly improved the enzyme’s stability, with the modified graphene oxide-lactoperoxidase composite retaining up to 31% of its initial activity even after 10 weeks of storage at 4°C, compared to the free enzyme, which lost all activity after 8 weeks.
Selective Anti-Cancer Activity of the Nanocomposite
The researchers then tested the anti-cancer potential of the graphene oxide-lactoperoxidase nanocomposite against both normal and colon cancer cell lines. The results were quite remarkable – the modified nanocomposite showed a potent and selective cytotoxic effect on the colon cancer cells, while having a much lower impact on the normal lung fibroblast cells.
Further investigation revealed that the nanocomposite induced apoptosis, or programmed cell death, in the colon cancer cells. This was evidenced by changes in the expression of key genes involved in cancer progression, such as the tumor suppressor gene p53 and the oncogene Bcl-2. The nanocomposite was also able to suppress the levels of pro-inflammatory markers, including IL-6, and NF-κB, which are known to contribute to tumor growth and metastasis.
Potential Impact and Future Directions
The findings of this study suggest that the graphene oxide-lactoperoxidase nanocomposite could offer a promising new approach for the treatment of colon cancer. The ability of the nanocomposite to selectively target and induce apoptosis in colon cancer cells, while minimizing harm to healthy cells, is a crucial advantage in developing more effective and safer cancer therapies.
Furthermore, the enhanced stability of the lactoperoxidase enzyme when incorporated into the nanocomposite could improve its therapeutic potential and expand its applications in the biomedical field. The researchers believe that this novel nanocomposite may serve as a platform for the delivery of other anti-cancer agents, further enhancing its therapeutic efficacy.
As with any new therapeutic approach, additional in-depth studies and clinical trials will be necessary to fully evaluate the safety and efficacy of the graphene oxide-lactoperoxidase nanocomposite for the treatment of colon cancer. However, the promising results of this study provide a strong foundation for continued research and development in this exciting field of cancer nanomedicine.
This article is based on research by AbdElAziz A. Nayl, Esmail M. El-Fakharany, Ahmed I. Abd-Elhamid, Wael A. A. Arafa, Ahmed H. Alanazi, Ismail M. Ahmed, Mohamed A. Abdelgawad, Ashraf A. Aly, Stefan Bräse.
For More Related Articles Click Here
